A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis

Trial Profile

A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Nuron Biotech
  • Most Recent Events

    • 12 Sep 2012 Planned End Date changed from 2 Dec 2013 to 2 Dec 2014 as reported by ClinicalTrials.gov record.
    • 11 Apr 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2012-03-002519).
    • 15 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-002683-24).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top